US52187K2006 - Common Stock
LEAP THERAPEUTICS INC
NASDAQ:LPTX (5/17/2024, 7:11:15 PM)
After market: 2.7 +0.07 (+2.66%)2.63
-0.11 (-4.01%)
Leap Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies designed to treat patients with cancer. The company is headquartered in Cambridge, Massachusetts and currently employs 44 full-time employees. The company went IPO on 2017-01-24. The firm is focused on developing targeted and immuno-oncology therapeutics. Its advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein. DKN-01 is being developed in patients with esophagogastric, gynecologic, and colorectal cancers. DKK1 modulates the Wnt/Beta-catenin and PI3kinase/AKT signaling pathways and promotes tumor proliferation, metastasis, angiogenesis, and in mediating an immune suppressive tumor microenvironment through enhancing the activity of myeloid-derived suppressor cells and downregulating NK cell ligands on tumor cells. The Company’s pipeline includes FL-301, a humanized monoclonal antibody targeting Claudin18.2, being developed in patients with gastric and pancreatic cancer. Claudin18.2 regulates barrier properties and contributes to cell-to-cell adhesion. The company also has preclinical antibody programs targeting Claudin18.2/CD137 and GDF15.
LEAP THERAPEUTICS INC
47 Thorndike St Ste B1-1
Cambridge MASSACHUSETTS 02141
P: 16172524343
CEO: Douglas E. Onsi
Employees: 44
Website: https://www.leaptx.com/
LPTX stock results show that Leap Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.
/PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported...
/PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced...
LPTX stock results show that Leap Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Leap Therapeutics (NASDAQ:LPTX) just reported results for the fourth quarter of...
/PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported...
Here you can normally see the latest stock twits on LPTX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: